Search | Page 3 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents

    ... of RBC transfusion independence (TI) ≥ 8 weeks. Secondary end points were RBC-TI ≥ 24 weeks, duration of RBC-TI, erythroid ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 07/18/2016 - 10:30am.

  2. Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and po

    ... and intermediate-1-risk) myelodysplastic syndromes (MDS) with poor prognostic features including anemia and/or ... according to International Working Group 2006 criteria. Secondary endpoints include overall survival, hematologic response including ...

    Research Article last updated 06/23/2016 - 10:17am.

  3. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

    ... of somatic mutations in myelodysplastic syndromes (MDS), the clinical relevance of variant allele frequency (VAF) for the ... genes in our training set of 219 patients with MDS or secondary acute myeloid leukemia with findings confirmed in a validation ...

    Research Article last updated 12/08/2015 - 1:04pm.

  4. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

    ... The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies ... (AML). AML, which can occur de novo as well as secondary to MDS, is characterized by malignant clones of myeloid lineage in ...

    Research Article last updated 12/09/2015 - 8:49am.

  5. Impact of the revised International Prognostic Scoring System cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndr

    ... in patients with myelodysplastic syndromes or secondary acute myeloid leukemia who were reported to the European Society for ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 03/02/2015 - 2:46pm.

  6. Transplants in Myelodysplastic Syndromes

    ... an increase in the prevalence of de novo but also of secondary forms after prior chemotherapy or radiotherapy, ... myelodysplastic syndromes (MDS) ...

    Research Article last updated 01/20/2015 - 1:10pm.

  7. Only particular cytogenetic events are related to disease progression in sequential cytogenetic studies in myelodysplastic syndromes.

    ... in 76 patients with myelodysplastic syndromes (MDS) followed up to 82 months. Their karyotypes were followed routinely, ... transformation or reduced survival, since the majority of secondary cytogenetic changes in evolutive karyotypes of our patients were ...

    Research Article last updated 07/09/2013 - 3:18pm.

  8. The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia.

    ... to the pathogenesis of myelodysplastic syndromes (MDS) and may trigger disease-progression to secondary acute myeloid leukemia (AML). Expression of apoptosis-mediators FAS ...

    Research Article last updated 11/14/2013 - 11:34am.

  9. Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy

    ... patients with myelodysplastic syndromes (MDS) treated with deferasirox . A secondary objective was to investigate the relationship between HRQOL, serum ... HRQOL of transfusion-dependent patients with MDS receiving deferasirox therapy remains stable over time. HRQOL assessment ...

    Research Article last updated 09/24/2014 - 10:50am.

  10. Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms

    ... as a discovery tool in myelodysplastic syndromes (MDS) has led to the identification of a large number of novel mutations. ... and identification of a subset of ancestral and secondary molecular lesions. Chromosomal gains and losses have been ... phenocopy. In addition to the search for somatic defects in MDS, similar discovery studies have been also performed to identify germ line ...

    Research Article last updated 03/03/2015 - 1:30pm.